- Mylan Laboratories has announced that it has reached a definitive agreement to acquire the assets of the US-based company Bertek, a manufacturer of transdermal drug systems. The medical products division of Bertek will provide Mylan with patents, a joint venture, and wound care and other products that will help fill the company's pipeline in generic as well as branded areas. The acquisition's cost was in the region of $39 million and will be accomplished through payment of Mylan common stock, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze